Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!
2024-2033 Forecast: What is the Projected Growth Rate for the Preclinical Assets Market?
The market size for preclinical assets has seen substantial growth in the past few years. There’s an anticipated growth from $5.32 billion in 2023 to $5.83 billion in 2024, with a compound annual growth rate (CAGR) of 9.7%. The historical growth can be linked to the need for drug development, progress in biotechnology, regulatory obligations, expansion in research funding, and coordinated research initiatives.
In the coming years, there is predicted to be significant growth in the preclinical assets market size, which is projected to reach $8.34 billion in 2028 with a compound annual growth rate (CAGR) of 9.3%. Factors contributing to this growth during the projected period include the development of precision medicine and personalized therapies, the integration of ai and machine learning, expansion of biobanking, attention towards rare diseases, as well as government initiatives and funds. Furthermore, emerging trends for the upcoming period encompass the rise of advanced imaging techniques, 3D organoid models, integration of multi-omics, improved predictive models, and the advancement of automation and high throughput screening.
Claim Your Free Sample of the Global Preclinical Assets Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12600&type=smp
What Are the Main Drivers Behind the Growth of the preclinical assets Market?
The surge in drug discovery activities is anticipated to spur the expansion of the preclinical asset market. Drug discovery is essentially the identification of chemical substances that could potentially serve as medicinal compounds. This process forms the crux of formulating new candidate medicines. In this context, preclinical assets are crucial as they provide pivotal data and empirical evidence, assisting in the selection of molecules for clinical trials. As an instance, the Regulatory Affairs Professionals Society, a United States regulatory body for healthcare and associated products, stated in January 2022 that 74% or 37 drugs were greenlighted by the US Food and Drug Administration (FDA) through at least one quickened channel in 2021, marking an increase from 68% of new drugs in 2020. Moreover, according to the Pharma R&D Annual Review 2022 released by Pharma Intelligence, a UK-based entity offering tools and services for pharmaceutical management, the number of drugs in the R&D pipeline saw growth from 17,737 in 2020 to 20,109 in 2022. Hence, the escalating rate of drug discovery is fueling the growth of the preclinical assets market.
What Are the Primary Segments of the Preclinical Assets Market?
1) By Service: Bioanalysis And DMPK (Drug Metabolism and Pharmacokinetic) studies, Toxicology Testing, Compound Management, Safety Pharmacology, Other Services
2) By Model Type: Patient Derived Organoid (PDO) Model, Patient Derived Xenograft Model
3) By End User: Biopharmaceutical Companies, Government Institutes, Other End-Users
Which Trends Are Revolutionizing the Preclinical Assets Market?
Product innovation is emerging as a crucial trend in the preclinical assets market. The predominant players in this market are zeroing in on creating innovative products and solutions to solidify their stance and gain a competitive edge. For example, Charles River Laboratories International, a US-based pharmaceutical establishment specializing in various preclinical and clinical labs, and Valo Health Inc., a US-based tech firm designed to revolutionize drug discovery, introduced Logica in April 2022. This is an AI-propelled drug solution that converts clients’ biological insights directly into optimized preclinical assets. Logica makes use of Charles River’s superior preclinical expertise and Valo’s AI-generated Opal Computational Platform to provide clients with revolutionary drug discovery via a solitary integrated service that smoothly converts targets into candidate nomination. By joining hands with Valo, Charles River fuses its lab proficiency with molecular design technology, introducing a profound shift in the field that benefits their customers with highly qualified leads and candidates, aligning client costs with value creation.
Order Now for Fast Delivery of Your Preclinical Assets Market Report!
https://www.thebusinessresearchcompany.com/report/preclinical-assets-global-market-report
Which Geographical Regions Are Pioneering Growth in the Preclinical Assets Market?
North America was the largest region in the preclinical assets market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preclinical assets market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The Preclinical Assets Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the preclinical assets market, its market share, and analyzes key competitors along with their market positions.
The Table Of Content For The Preclinical Assets Market Include
1. Preclinical Assets Market Executive Summary
2. Preclinical Assets Market Segments
3. Preclinical Assets Market Size And Template Market Growth Rate
4. Key Preclinical Assets Market Trends
5. Major Preclinical Assets Market Drivers
……
25. Key Mergers And Acquisitions In The Preclinical Assets Market
26. Top Preclinical Assets Companies
27. Preclinical Assets Market Opportunities And Strategies
28. Preclinical Assets Market, Conclusions And Recommendations
29. Appendix
Discover Related Reports by The Business Research Company:
Clinical Data Management Systems (CDMS) Global Market Report 2024
Clinical Microbiology Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/clinical-microbiology-global-market-report
Preclinical CRO Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/preclinical-cro-global-market-report
Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
